Olivera Finn

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Prophylactic cancer vaccines
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, W1142 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Curr Opin Immunol 14:172-7. 2002
  2. ncbi request reprint Cancer vaccines: accomplishments and challenges
    Sharmila Pejawar-Gaddy
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Crit Rev Oncol Hematol 67:93-102. 2008
  3. doi request reprint Cancer immunology
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, Pittsburgh, PA 15261, USA
    N Engl J Med 358:2704-15. 2008
  4. pmc Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells
    Anda M Vlad
    Department of Immunology, University of Pittsburgh School of Medicine, Biomedical Science Tower, Terrace and DeSoto Streets, Pittsburgh, PA 15261, USA
    J Exp Med 196:1435-46. 2002
  5. pmc Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells
    H Kao
    Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA 15261, USA
    J Exp Med 194:1313-23. 2001
  6. pmc Preventive immunization of aged and juvenile non-human primates to β-amyloid
    Julia Kofler
    Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Neuroinflammation 9:84. 2012
  7. pmc Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance
    Olivera J Finn
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Exp Mol Pathol 93:315-8. 2012
  8. pmc MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
    Takashi Kimura
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 6:18-26. 2013
  9. ncbi request reprint Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
    O J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh 15261, USA
    Ann Oncol 23:viii6-9. 2012
  10. ncbi request reprint Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1040 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Immunol Res 50:261-8. 2011

Research Grants

  1. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2006
  2. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2010
  3. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2004
  4. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2000
  5. HUMAN T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 1993
  6. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2009
  7. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2010
  8. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2011
  9. Training/Cellular/Molecular Mechanisms/Tumor Rejection
    Olivera Finn; Fiscal Year: 2007
  10. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2005

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Prophylactic cancer vaccines
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, W1142 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Curr Opin Immunol 14:172-7. 2002
    ..Transgenic mouse models are providing encouraging indications of future usefulness of vaccines that are based on these molecules...
  2. ncbi request reprint Cancer vaccines: accomplishments and challenges
    Sharmila Pejawar-Gaddy
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Crit Rev Oncol Hematol 67:93-102. 2008
    ..In this review, we address main issues that have driven development of cancer vaccines and the challenges that have been met and/or are anticipated...
  3. doi request reprint Cancer immunology
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, Pittsburgh, PA 15261, USA
    N Engl J Med 358:2704-15. 2008
  4. pmc Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells
    Anda M Vlad
    Department of Immunology, University of Pittsburgh School of Medicine, Biomedical Science Tower, Terrace and DeSoto Streets, Pittsburgh, PA 15261, USA
    J Exp Med 196:1435-46. 2002
    ..Glycopeptides that are presented on DCs are recognized by T cells. This suggests that a much broader repertoire of T cells could be elicited against MUC1 and other glycoproteins than expected based only on their peptide sequences...
  5. pmc Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells
    H Kao
    Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh, PA 15261, USA
    J Exp Med 194:1313-23. 2001
    ....
  6. pmc Preventive immunization of aged and juvenile non-human primates to β-amyloid
    Julia Kofler
    Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Neuroinflammation 9:84. 2012
    ....
  7. pmc Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance
    Olivera J Finn
    University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Exp Mol Pathol 93:315-8. 2012
    ..This new immunology and pathology alliance named "Immunoscore" will advance research in both disciplines as well as benefit patients...
  8. pmc MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study
    Takashi Kimura
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 6:18-26. 2013
    ..g., high levels of MDSC) might already exist in some individuals, suggesting an even earlier premalignant stage or preselection of nonimmunosuppressed patients for prophylactic vaccination...
  9. ncbi request reprint Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
    O J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh 15261, USA
    Ann Oncol 23:viii6-9. 2012
    ..Most exciting of all, these successes provide a rationale to expect that used in various combinations or earlier in disease, current and future immunotherapies may transform cancer treatment, improving a prognosis for many patients...
  10. ncbi request reprint Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, E1040 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Immunol Res 50:261-8. 2011
    ....
  11. ncbi request reprint Human tumor antigens, immunosurveillance, and cancer vaccines
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Immunol Res 36:73-82. 2006
    ....
  12. ncbi request reprint Immunology in Pittsburgh
    Olivera J Finn
    E1040 Biomedical Science Tower, University of of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Immunol Res 36:1-2. 2006
    ..A large number of outstanding young investigators, as well as several well-established tumor immunologists, were recruited to Pittsburgh at that time...
  13. pmc Premalignant lesions as targets for cancer vaccines
    Olivera J Finn
    University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA 15261, USA
    J Exp Med 198:1623-6. 2003
  14. ncbi request reprint Human tumor immunology at the molecular divide
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Immunol 178:2615-6. 2007
  15. ncbi request reprint Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004
    Olivera J Finn
    Department of Immunology, E1040 Biomedical Science Tower, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Immunol Immunother 54:287-9. 2005
  16. ncbi request reprint History of tumour vaccines and novel approaches for preventive cancer vaccines
    O Finn
    University of Pittsburgh Cancer Institute, Pittsburg, PA 15261, USA
    Dev Biol (Basel) 116:3-12. 2004
  17. ncbi request reprint Cancer vaccines: between the idea and the reality
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, E1040 Biomedical Science Tower, Pittsburgh, Pennsylvania 15261, USA
    Nat Rev Immunol 3:630-41. 2003
    ..Considering how refractory cancer has been to standard therapy, efforts to achieve immune control of this disease are well justified...
  18. pmc Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution
    Nehad M Alajez
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Blood 105:4583-9. 2005
    ..Reconstituted mice controlled the outgrowth of a MUC1-transfected but not the parental control tumor. scTCR expression appears lifelong, suggesting a successful transduction of the self-renewing stem cells...
  19. pmc Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (-/-) mice
    Laura A Vella
    Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA
    Ann N Y Acad Sci 1174:68-73. 2009
    ..We demonstrate that cyclin B1 vaccination delays spontaneous cyclin B1(+) tumor growth and increases median survival of tumor-bearing p53(-/-) mice...
  20. pmc Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer
    Pamela L Beatty
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Prev Res (Phila) 3:438-46. 2010
    ..This suggests that the tumor-promoting microenvironment of chronic inflammation can be converted to a tumor-inhibiting environment by increasing adaptive immunity against a disease-associated antigen...
  21. ncbi request reprint DNA vaccines for cancer too
    Min Yu
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Immunol Immunother 55:119-30. 2006
  22. ncbi request reprint Cancer vaccines: a promising cancer therapy against all odds
    Ann Willman Silk
    School of Medicine, Office of Medical Education, University of Pittsburgh, M 211 Scaife Hall, Pittsburgh, PA 15261, USA
    Future Oncol 3:299-306. 2007
    ..At the very least, it should be given primary consideration in situations where the role of cytotoxic chemotherapy is equivocal and patients are in need of a nontoxic alternative...
  23. ncbi request reprint Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation
    Adam M Farkas
    Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, 200 Lothrop St, Pittsburgh, PA 15261, USA
    Semin Immunol 22:125-31. 2010
    ..Collectively this work shows that it is possible to design vaccines based on tumor-associated antigens and elicit effective immunity against abnormal expression of these antigens on tumors without causing autoimmunity...
  24. ncbi request reprint Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer
    Ann Marie Egloff
    Department of Immunology, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA
    Cancer Res 66:6-9. 2006
    ..We review evidence that the immune system recognizes some abnormally expressed cyclins as tumor antigens, such as cyclin B1, and we analyze the potential of cyclins D, E, and A to serve a similar function in cancer immunosurveillance...
  25. pmc Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer
    Laura A Vella
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Proc Natl Acad Sci U S A 106:14010-5. 2009
    ..We found that cyclin B1 DNA prime-protein boost vaccine protected mice from a challenge with a tumor cell line that was established from a tumor arising in the p53(-/-) mouse that spontaneously overexpresses cyclin B1...
  26. ncbi request reprint Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53
    Min Yu
    Department of Immunology, W1142 Biomedical Science Tower, University of Pittsburgh School of Medicine, PA 15261, USA
    Mol Immunol 38:981-7. 2002
    ..We conclude that p53 plays an important role in cyclin B1 regulation and that tumors with mutated p53 will be good candidates for cyclin B1 based immunotherapy...
  27. ncbi request reprint Cancer vaccines: emphasis on pediatric cancers
    Terri Guinipero
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15262, USA
    Curr Pharm Des 16:292-9. 2010
    ..In this review, we discuss the current efforts at designing and testing cancer vaccines in children with the focus on specific tumor antigens expressed by pediatric cancers...
  28. ncbi request reprint Tumor antigen-based immunotherapy and immunoprevention of cancer
    Sean O Ryan
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Int Arch Allergy Immunol 142:179-89. 2007
    ....
  29. ncbi request reprint T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease
    Hiroyuki Suzuki
    Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15261, USA
    Clin Cancer Res 11:1521-6. 2005
    ....
  30. ncbi request reprint Tumor antigens and tumor antigen discovery
    Daniel F Graziano
    University of Pittsburgh, Pittsburgh, PA 15261, USA
    Cancer Treat Res 123:89-111. 2005
  31. pmc Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles
    Sharmila Pejawar-Gaddy
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Immunol Immunother 59:1685-96. 2010
    ..Immunization of human MUC1 transgenic mice, where MUC1 is a self-antigen, with the VLP vaccine induced MUC1-specific CTL, delayed the growth of MUC1 transplanted tumors and elicited complete tumor rejection in some animals...
  32. pmc Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses
    Sean O Ryan
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15262, USA
    Cancer Res 70:5788-96. 2010
    ..This represents an important consideration for designing safe and effective cancer vaccines...
  33. ncbi request reprint Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer
    Pamela L Beatty
    Department of Immunology, University of Pittsburgh School of Medicine, PA 15261, USA
    J Immunol 179:735-9. 2007
    ....
  34. ncbi request reprint Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells
    Michael S Turner
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Immunol 178:2787-93. 2007
    ..Our data suggest that the balance between Th and regulatory T cells is a critical parameter that could be modulated to improve the response to cancer vaccines...
  35. ncbi request reprint Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
    Ramesh K Ramanathan
    UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 562, Pittsburgh, PA 15232, USA
    Cancer Immunol Immunother 54:254-64. 2005
    ..Further evaluation is warranted to examine the effect on disease-free survival and overall survival, especially in early disease and in the absence of immunosuppressive standard therapy...
  36. ncbi request reprint Glycoprotein tumor antigens for immunotherapy of breast cancer
    Anda M Vlad
    Department of Immunology, University of Pittsburgh School of Medicine, E1040 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Breast Dis 20:73-9. 2004
    ..We discuss here some of the new therapeutic strategies for exploiting abnormal glycosylation pathways in tumors and using defined carbohydrate and/or glycoprotein tumor antigens in active specific immunotherapy of breast cancer...
  37. ncbi request reprint MUC1 immunobiology: from discovery to clinical applications
    Anda M Vlad
    Department of Immunology, University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania 15261, USA
    Adv Immunol 82:249-93. 2004
  38. doi request reprint Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy
    Xiaochuan Chen
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Cancer Immunol Immunother 58:977-87. 2009
    ..Both scTCR and HSV-TK-EGFP genes were functional in the transduced cells, as evidenced by their specific recognition of MUC1(+) tumors and efficient eradication by ganciclovir...
  39. ncbi request reprint Immunological weapons acquired early in life win battles with cancer late in life
    Olivera J Finn
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Immunol 181:1589-92. 2008
  40. ncbi request reprint Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice
    Sean O Ryan
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Biol Chem 390:611-8. 2009
    ..We conclude that MUC1 glycopeptides induce stronger immunity in MUC1-Tg mice because they are recognized as 'foreign' rather than ;self' and because they are cross-presented preferentially by DCs...
  41. ncbi request reprint Mucins in gastrointestinal cancers
    Michael S Turner
    Department of Immunology, University of Pittsburgh School of Medicine, Cancer Center, PA 15261, USA
    Cancer Chemother Biol Response Modif 21:259-74. 2003
    ..This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future...
  42. pmc Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis
    Deepak K Kadayakkara
    Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA
    Pancreas 39:510-5. 2010
    ..MUC1 is also expressed on pancreatic ductal epithelia. We tested the possibility that in IBD, MUC1 expression on pancreatic ducts is also abnormal leading to inflammation and pancreatitis...
  43. ncbi request reprint Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer
    Ann Marie Egloff
    University of Pittsburgh School of Medicine, E1040 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Ann N Y Acad Sci 1062:29-40. 2005
    ....
  44. ncbi request reprint Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity
    Casey A Carlos
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    J Immunol 175:1628-35. 2005
    ....
  45. ncbi request reprint Tumor immunology at the service of cancer immunotherapy
    Olivera J Finn
    Curr Opin Immunol 16:127-9. 2004
  46. pmc Cross-priming of cyclin B1, MUC-1 and survivin-specific CD8+ T cells by dendritic cells loaded with killed allogeneic breast cancer cells
    Hiroaki Saito
    Baylor Institute for Immunology Research, Live Oak, Dallas, Texas 75024, USA
    Breast Cancer Res 8:R65. 2006
    ..The ability of dendritic cells (DCs) to take up whole tumor cells and process their antigens for presentation to T cells ('cross-priming') is an important mechanism for induction of tumor specific immunity...
  47. pmc Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration
    Isabel Correa
    Cancer Research UK, Breast Cancer Biology Group, Guy s Hospital, London, UK
    Immunology 108:32-41. 2003
    ..The concentration of MUC1 at the leading edge of polarized activated human T cells suggests that MUC1 could be involved in early interactions between T cells and endothelial cells at inflammatory sites...
  48. ncbi request reprint Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer
    Kathryn L Terry
    Obstetrics and Gynecology Epidemiology Center, Brigham and Women s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 16:30-5. 2007
    ..In this study, we examined whether the total number of ovulatory cycles decreases the likelihood of anti-MUC1 antibodies and provides an immune basis for the association between "incessant ovulation" and ovarian cancer risk...

Research Grants20

  1. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2006
    ..This can now be examined in relevant animal models, MUC1 and HLA transgenic mice that develop spontaneous MUC1 + tumors. ..
  2. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2010
    ..Nobody has yet considered MUC1 as a target for therapy, and specifically immunotherapy, of chronic inflammatory diseases that carry increased risk of cancer. ..
  3. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2004
    ..This can now be examined in relevant animal models, MUC1 and HLA transgenic mice that develop spontaneous MUC1 + tumors. ..
  4. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2000
    ..In vivo correlates to these experiments will be performed in C57BL/6 and C57BL/6-MUC-1 transgenic mice. ..
  5. HUMAN T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 1993
    ..The long term goals of the project are to fully understand the anti-tumor mucin response and its potential for immunotherapy...
  6. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2009
    ....
  7. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2010
    ....
  8. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera J Finn; Fiscal Year: 2011
    ..In this renewal application, work will be done to show that this form of immunotherapy and the same vaccines may be useful not only for cancer but also for treatment and prevention of chronic inflammations that increase risk for cancer. ..
  9. Training/Cellular/Molecular Mechanisms/Tumor Rejection
    Olivera Finn; Fiscal Year: 2007
    ..Writing grant proposals to various private and government funding agencies; 3. Teaching in courses related to their field of expertise. ..
  10. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2005
    ..This can now be examined in relevant animal models, MUC1 and HLA transgenic mice that develop spontaneous MUC1 + tumors. ..
  11. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 1999
    ..In vivo correlates to these experiments will be performed in C57BL/6 and C57BL/6-MUC-1 transgenic mice. ..
  12. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2003
    ..This can now be examined in relevant animal models, MUC1 and HLA transgenic mice that develop spontaneous MUC1 + tumors. ..
  13. T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 2002
    ..This can now be examined in relevant animal models, MUC1 and HLA transgenic mice that develop spontaneous MUC1 + tumors. ..
  14. HUMAN T CELL IMMUNITY TO EPITHELIAL TUMOR MUCINS
    Olivera Finn; Fiscal Year: 1992
    ..The long term goals of the project are to fully understand the anti-tumor mucin response and its potential for immunotherapy...